Lupin launches levothyroxine sodium tablets in US
Pharma major Lupin launched Levothyroxine tablets for which is had earlier received USFDA approval. The tablets are used to treat hypothyroidism and pituitary thyrotropin suppression.
Lupin's Levothyroxine sodium tablets USP, is the generic equivalent of AbbVie, Inc's Synthroid Tablets. The given medicine is indicated for hypothyroidism and pituitary thyrotropin suppression. It is prescribed as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. While in pituitary thyrotropin suppression it is used as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Levothyroxine Sodium Tablets, 25 meg, SO meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg, and 300 meg had an annual sales of approximately US$ 2.5 billions in the US market (IQVIA MAT January 2019).
Lupin is engaged in developing and delivering branded and generic formulations. It also further produces biotechnology products and APIs, globally.
On Friday, the stock closed at Rs. 743.55, down 1.20 per cent on BSE. The benchmark index Sensex ended on negative note down 222.14 points at 38,164.61.